NCT04072445 - Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

August 13, 2021

Study Completion Date

August 13, 2021

Conditions

Advanced Bile Duct CarcinomaAdvanced Gallbladder CarcinomaRefractory Bile Duct CarcinomaRefractory Gallbladder CarcinomaStage III Distal Bile Duct Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage III Intrahepatic Bile Duct Cancer AJCC v8Stage IIIA Distal Bile Duct Cancer AJCC v8Stage IIIA Gallbladder Cancer AJCC v8Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8Stage IIIB Distal Bile Duct Cancer AJCC v8Stage IIIB Gallbladder Cancer AJCC v8Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8Stage IV Distal Bile Duct Cancer AJCC v8Stage IV Gallbladder Cancer AJCC v8Stage IV Intrahepatic Bile Duct Cancer AJCC v8Stage IVA Gallbladder Cancer AJCC v8Stage IVB Gallbladder Cancer AJCC v8

Interventions

DRUG

Irinotecan

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

Trial Locations (1)

55905

Mayo Clinic, Rochester